Why the study?
Does antiarrhythmic drug therapy reduce the rate of sudden death in patients with asymptomatic or mildly symptomatic ventricular ectopic activity after myocardial infarction?
Does antiarrhythmic drug therapy reduce the rate of sudden death in patients with asymptomatic or mildly symptomatic ventricular ectopic activity after myocardial infarction?
Answers are grounded in this paper and cite their sources.
The preliminary results of CAST challenge conventional wisdom regarding the suppression of ventricular ectopic activity post-myocardial infarction.
The Cardiac Arrhythmia Suppression Trial (CAST) was designed to examine the hypothesis that suppressing asymptomatic or mildly symptomatic ventricular ectopic activity after myocardial infarction would reduce the rate of sudden death. CAST, which was preceded by a well-designed feasibility study, the Cardiac Arrhythmia Pilot Study,1 is the first long-term, multicenter, multidrug, placebo-controlled trial of the safety and efficacy of antiarrhythmic drug therapy in reducing the risk of sudden death.2 The preliminary results, as presented in the media and in expanded form in this issue of the Journal,2 have astounded most observers and challenge much of the conventional wisdom about . . .
No takes yet. Share an insight, caveat, or question.
Jeremy N. Ruskin (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: